Key Highlights

Risk & Performance

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Phase 3

4(80.0%)

N/A

1(20.0%)

5Total

Phase 3(4)

N/A(1)

Loading network data...

Showing 5 of 5 trials

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Role: collaborator

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Role: collaborator

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Role: collaborator

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

Role: collaborator

Study of STYLAGE® XXL for Volume Deficiency in the Mid-Face

Role: collaborator

All 5 trials loaded